Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Profound Medical Corp.NASDAQ: PROF
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $100K fell 38.7% year over year, behind the -27.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 9.6% from the prior quarter. Over 3 fiscal years it compounded at -29.2% a year.
Context
- Depreciation & amortization amounted to 3.5% of revenue in FY2025, down 5.7 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -38.7% toward the trailing-twelve-month pace of -27.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 569.8K USD
- Year-over-year change
- -39.1%
- 4-year CAGR
- -25.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 569.8K | -39.1% |
| FY2024 | 2024-12-31 | 936K | +0.8% |
| FY2023 | 2023-12-31 | 929K | -42.1% |
| FY2022 | 2022-12-31 | 1.6M | -14.6% |
| FY2021 | 2021-12-31 | 1.88M | — |
Depreciation & Amortization vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's LTM Mar 2026 depreciation & amortization of $499.37K is the smallest of the 11 companies compared; the peer median is $3.47M.
- Its year-over-year change of -27.3% is the 9th highest of 10, against a peer median of +7.8%.
- Depreciation & amortization amounts to 2.6% of revenue for PROF, versus a peer median of 11.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $4.68M | +4.5% | +24.0% | 14.5% | |
| LTM Mar 2026 | $4.56M | +11.6% | +9.7% | 7.9% | |
| LTM Mar 2026 | $3.97M | — | -20.6% | 3.5% | |
| LTM Mar 2026 | $3.65M | +35.4% | +111.4% | 589.8% | |
| LTM Mar 2026 | $3.3M | +36.1% | +28.1% | 2.2% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.69M | +7.8% | +29.0% | 91.1% |
| LTM Mar 2026 | $1.61M | +16.3% | +19.7% | 54.5% | |
| LTM Mar 2026 | $627K | -41.1% | -39.6% | 0.6% | |
| LTM Mar 2026 | $589K | -20.5% | +16.3% | 1.3% | |
| LTM Mar 2026 | $499.37K | -27.3% | -29.2% | 2.6% | |
| Peer median (excluding PROF) | $3.47M | +7.8% | +18.0% | 11.2% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.7M) | (28.67M) | (28.32M) | (27.82M) | (42.57M) |
| Depreciation & Amortization | 1.88M | 1.6M | 929K | 936K | 569.8K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.21M | 4.24M | 3.42M | 2.58M | 5.49M |
| Change in Working Capital | (877K) | (5.63M) | 540K | 591K | (1.74M) |
| Accounts Receivables | 2M | (1.42M) | (956K) | 186K | (175.01K) |
| Inventory | (2.49M) | (1.86M) | 353K | 656K | (2.87M) |
| Accounts Payables | (356K) | (566K) | 1.35M | 815K | 384.62K |
| Other Working Capital | (26K) | (1.78M) | (211K) | (1.07M) | 918.81K |
| Other Non-Cash Items | 132K | 2.66M | 828K | 255K | (622.65K) |
| Operating Cash Flow | (22.36M) | (25.8M) | (22.61M) | (23.45M) | (38.88M) |
| Capital Expenditures | (593K) | 0 | 0 | 0 | (179.08K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (561K) | 0 | 0 | 0 | 91.63K |
| Investing Cash Flow | (593K) | 0 | 0 | 0 | (246.24K) |
| Debt Repayment | (386K) | 6.92M | (912K) | (2.56M) | (1.33M) |
| Common Stock Issued | 0 | 0 | 0 | 62.11M | 43.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.33M | 114K | 2.67M | (4.85M) | 0 |
| Financing Cash Flow | 5.95M | 7.03M | 1.76M | 54.7M | 41.86M |
| Effect of Forex Changes | 244K | (1.87M) | 549K | (2.54M) | 2M |
| Net Change in Cash | (16.76M) | (20.64M) | (20.3M) | 28.7M | 4.73M |
| Free Cash Flow | (22.95M) | (25.8M) | (22.61M) | (23.45M) | (39.05M) |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.